Vasquez 2009

Methods	Individually RCT Dates of trial: April 2007 to Feb 2008.
Participants	50 people with uncomplicated P. falciparum diagnosis by thick blood slide, 150 to 50,000 parasites/μL Age one year and over, both sexes. Exclusion criteria: pregnant, mixed infection, danger signs and complications, allergy to antimalarials, serious illness at time or presentation, antimalarial treatment in last 72 hrs, MQ in last four weeks.
Interventions	1. AS+MQ Age 1 to 6: AS 50 mg on days 1, 2, 3 (reported as 0, 1, 2); MQ 250 mg on day 2. Age 7 to 13: AS 100 mg on days 1, 2, 3, MQ 250 mg on days 1, 2, 3. Age = 13: AS 200 mg on days 1, 2, 3, MQ 500 mg on days 1, 2, 3. 2. AS+MQ+PQ As above plus PQ: Age 1 to 6: 0.3-0.6 mg/kg day 3 (reported as day 2). Age 7 to 13: 22.5 mg/kg day 3. Age = 13: 45 mg day 3.
Outcomes	Assessed on days 2, 3, 4, 8, 15, 22, 29, 36, and 43. 1. Clinical recurrence. 2. Parasitemia prevalence. 3. Parasite density. 4. Fever resolution. 5. Prevalence of gametocytes. 6. Density of gametocytes. 7. Adverse effects.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Seems to be alternate allocation following order of arrival ("segun el orden de llegada").
Allocation concealment (selection bias)	Unclear risk	Not clear.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts noted.
Selective reporting (reporting bias)	Low risk	No evidence of bias.
Other bias	Low risk	No suggestion of other bias.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Does not seem to be blinded ("con determination no ciega del efecto en grupos iguales").
Blinding of outcome assessment (detection bias) All outcomes	High risk